MedTrace Logo

Phase 1 Study of ANAVEX3-71

NCT04442945 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-01-19

No results posted yet for this study

Summary

A first in human phase 1 study in healthy volunteers to assess ANAVEX3-71 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics

Conditions

  • Healthy

Interventions

DRUG

ANAVEX3-71

Active oral dose of ANAVEX3-71

DRUG

Placebo

Oral placebo

Sponsors & Collaborators

  • Anavex Australia Pty Ltd.

    collaborator INDUSTRY

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2021-09-30
Completion
2021-10-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04442945 on ClinicalTrials.gov